Cargando…
Disease site number was not prognostic in a low-risk Hodgkin lymphoma combined modality trial: revisiting PHC HOD90
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The American Society of Hematology
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637876/ https://www.ncbi.nlm.nih.gov/pubmed/37647596 http://dx.doi.org/10.1182/bloodadvances.2023010944 |
| _version_ | 1785133491815448576 |
|---|---|
| author | Feraco, Angela M. Zhou, Yiwang Zheng, Ying Marks, Lianna J. Friedmann, Alison Weinstein, Howard J. Link, Michael P. Flerlage, Jamie E. |
| author_facet | Feraco, Angela M. Zhou, Yiwang Zheng, Ying Marks, Lianna J. Friedmann, Alison Weinstein, Howard J. Link, Michael P. Flerlage, Jamie E. |
| author_sort | Feraco, Angela M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10637876 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | The American Society of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-106378762023-11-11 Disease site number was not prognostic in a low-risk Hodgkin lymphoma combined modality trial: revisiting PHC HOD90 Feraco, Angela M. Zhou, Yiwang Zheng, Ying Marks, Lianna J. Friedmann, Alison Weinstein, Howard J. Link, Michael P. Flerlage, Jamie E. Blood Adv Research Letter The American Society of Hematology 2023-09-01 /pmc/articles/PMC10637876/ /pubmed/37647596 http://dx.doi.org/10.1182/bloodadvances.2023010944 Text en © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Research Letter Feraco, Angela M. Zhou, Yiwang Zheng, Ying Marks, Lianna J. Friedmann, Alison Weinstein, Howard J. Link, Michael P. Flerlage, Jamie E. Disease site number was not prognostic in a low-risk Hodgkin lymphoma combined modality trial: revisiting PHC HOD90 |
| title | Disease site number was not prognostic in a low-risk Hodgkin lymphoma combined modality trial: revisiting PHC HOD90 |
| title_full | Disease site number was not prognostic in a low-risk Hodgkin lymphoma combined modality trial: revisiting PHC HOD90 |
| title_fullStr | Disease site number was not prognostic in a low-risk Hodgkin lymphoma combined modality trial: revisiting PHC HOD90 |
| title_full_unstemmed | Disease site number was not prognostic in a low-risk Hodgkin lymphoma combined modality trial: revisiting PHC HOD90 |
| title_short | Disease site number was not prognostic in a low-risk Hodgkin lymphoma combined modality trial: revisiting PHC HOD90 |
| title_sort | disease site number was not prognostic in a low-risk hodgkin lymphoma combined modality trial: revisiting phc hod90 |
| topic | Research Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637876/ https://www.ncbi.nlm.nih.gov/pubmed/37647596 http://dx.doi.org/10.1182/bloodadvances.2023010944 |
| work_keys_str_mv | AT feracoangelam diseasesitenumberwasnotprognosticinalowriskhodgkinlymphomacombinedmodalitytrialrevisitingphchod90 AT zhouyiwang diseasesitenumberwasnotprognosticinalowriskhodgkinlymphomacombinedmodalitytrialrevisitingphchod90 AT zhengying diseasesitenumberwasnotprognosticinalowriskhodgkinlymphomacombinedmodalitytrialrevisitingphchod90 AT marksliannaj diseasesitenumberwasnotprognosticinalowriskhodgkinlymphomacombinedmodalitytrialrevisitingphchod90 AT friedmannalison diseasesitenumberwasnotprognosticinalowriskhodgkinlymphomacombinedmodalitytrialrevisitingphchod90 AT weinsteinhowardj diseasesitenumberwasnotprognosticinalowriskhodgkinlymphomacombinedmodalitytrialrevisitingphchod90 AT linkmichaelp diseasesitenumberwasnotprognosticinalowriskhodgkinlymphomacombinedmodalitytrialrevisitingphchod90 AT flerlagejamiee diseasesitenumberwasnotprognosticinalowriskhodgkinlymphomacombinedmodalitytrialrevisitingphchod90 |